Manu Kanwar
About Manu Kanwar
Manu Kanwar serves as the Director of Process Development at Kite Pharma, a position he has held since 2020. He has extensive experience in the biopharmaceutical industry, having previously worked at Gilead Sciences and Bristol-Myers Squibb.
Work at Kite Pharma
Manu Kanwar has been serving as the Director of Process Development at Kite Pharma since 2020. In this role, he oversees the development and optimization of manufacturing processes for cell therapy products. His expertise contributes to advancing Kite Pharma's mission in the field of oncology, focusing on innovative therapies that utilize the body's immune system to fight cancer.
Previous Experience at Gilead Sciences
Prior to his current position, Manu Kanwar worked at Gilead Sciences as the Function Head of Cell Line Development from 2015 to 2020. In this capacity, he led initiatives to develop and optimize cell lines for biopharmaceutical production. His leadership played a crucial role in enhancing the efficiency and effectiveness of the development process.
Career at Bristol-Myers Squibb
Manu Kanwar was employed at Bristol-Myers Squibb as a Scientist from 2011 to 2015. During his tenure, he contributed to various research projects focused on drug development and optimization. His work involved applying scientific principles to advance the company's therapeutic offerings.
Educational Background
Manu Kanwar holds a Bachelor of Engineering in Chemical Engineering from Panjab University, Chandigarh, which he completed from 1998 to 2002. He further pursued his education at The Johns Hopkins University, where he earned a Doctor of Philosophy in Engineering between 2005 and 2011. His academic background provides a strong foundation for his professional expertise in process development.
Internship Experience at Genentech
In 2007, Manu Kanwar gained practical experience as a Graduate Intern at Genentech for 11 months. This internship allowed him to apply his academic knowledge in a real-world setting, contributing to his professional development in the biotechnology industry.